Children aged <3 years with IgE-mediated CMPA (symptoms of IgE-mediated allergy, SPT ≥ 3 mm with negative control 0 mm and/or sIgE > 0.35 kUA/L), treated between 2011–2021. This evidence concerns the gene IGHE and allergic disease.